A5001424781- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Nicotinic Acetylcholine Receptors Study
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Bioactive Compounds and Antitumor Agents
- Advanced MRI Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- DNA Repair Mechanisms
- Transgenic Plants and Applications
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Click Chemistry and Applications
- Advanced Biosensing Techniques and Applications
- Calcium signaling and nucleotide metabolism
Providence Portland Medical Center
2024-2025
Oregon Health & Science University
2017-2024
The University of Texas MD Anderson Cancer Center
2019-2022
University of California, Los Angeles
2015-2018
Memorial Healthcare System
2017
University of California, Irvine
2017
Sansum Medical Clinic
2017
Redondo Optics (United States)
2017
St. John's School
2017
National Cancer Institute
2011
715 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results from cohort PC BRCA1/2 mut treated N+I are reported. Methods: Eligible had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options or prior immune checkpoint inhibitor tx. PD-L1 expression testing was not required. Genomic performed CLIA-certified,...
Abstract Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity enhance clinical management. We applied Evolutionary Action Score functionally characterize TP53 mutations (EAp53) in 96 TNBC and observed that EAp53 stratification may identify associated with worse outcomes. These findings merit further exploration larger cohorts treated neoadjuvant chemotherapy regimens.
Abstract Background: ctDNA monitoring during adjuvant endocrine therapy provides an opportunity to detect molecular relapse before clinically apparent recurrence. The rate and dynamics of positivity the frequency asymptomatic but imaging detectable metastatic disease at time detection remain unknown in high-risk ER+/HER2- breast cancers. We present results rates 508 ctDNA+ patients from a prospective, multicenter, randomized surveillance intervention trial, DARE (NCT04567420). Patients...
Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor 2-negative (HR+/HER−) metastatic breast cancer (MBC). However, next-line strategies after CDKi progression are not yet optimized. We report here impact clinical and genomic factors on post-CDKi outcomes in a single institution cohort HR+/HER2− MBC. Methods retrospectively reviewed medical records MBC that received...
Improving outcomes for patients with human epidermal growth factor 2-positive (HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This trial evaluated a novel combination of everolimus, lapatinib and capecitabine this disease.Patients trastuzumab-pretreated, HER2+ breast cancer brain metastasis without prior therapy mammalian target rapamycin (mTOR) inhibitor were eligible. Patients received everolimus daily (continuously) twice (d1-14) in 21-d cycles. The primary...
Smoking is the leading cause of preventable cancer deaths in United States. Nicotine replacement therapies (NRT) have been developed to aid smoking cessation, which decreases lung incidence. However, safety NRT controversial because numerous preclinical studies shown that nicotine enhances tumor cell growth vitro and vivo. We modeled mice determine effects physiologic levels on formation, growth, or metastasis. administered drinking water did not enhance tumorigenesis after treatment with...
Genetic rearrangements involving FLT3 are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) chronic myeloproliferative disorders. Here we report two cases fusions patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, was fused a new fusion partner MYO18A patient marrow most consistent atypical myeloid leukemia; second case ETV6-FLT3 observed bone myelomonocytic leukemia. Notably,...
3131 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results small cohort solid tumors NRG1 fusions treated afatinib are reported. Methods: Eligible had measurable, disease, NRG1fusion, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Pts non-small cell lung cancer (NSCLC) were eligible if they pathogenic mutations ALK, BRAF,...
Abstract Purpose: The immunological profile of early-stage breast cancer treated with neoadjuvant PARP inhibitors has not been described. aim this study was to delineate the changes in tumor immune microenvironment (TiME) induced by talazoparib. Patients and Methods: operable germline BRCA1/2 pathogenic variant (gBRCA1/2+) were enrolled a feasibility Thirteen patients who received 8 weeks talazoparib available for analysis, including 11 paired pre- post-talazoparib core biopsies....
12141 Background: Chemotherapy-induced alopecia significantly impacts quality of life (QOL). First-generation scalp cooling systems PAXMAN and Dignicap, while effective in reducing alopecia, are not universally adopted due to their lack portability. Amma is a second-generation, portable battery-powered system that offers the opportunity for widespread clinical usage by allowing self-administration mobility. Here, we report first-in-human outcomes preliminary cohort receiving curative-intent...
3142 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort solid tumors ERBB2/3amp or mut treated P+T are reported. Methods: Eligible had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Dosing P 840 mg IV over 60...
3130 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort solid tumors HTMB treated N+I are reported. Methods: Eligible had measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options or prior immune checkpoint inhibitor tx. PD-L1 expression testing was not required. Genomic performed CLIA-certified,...
Motivation: Determine best-practice quantitative DCE-MRI for predicting breast cancer (BC) response to neoadjuvant chemotherapy (NAC) in a multi-center (MC) and multi-vendor platform (MP) setting. Goal(s): Evaluate effects of different pharmacokinetic analysis approaches on Ktrans its predictive performance. Approach: 15 BC patients treated with NAC underwent longitudinal at 3 sites using 3T systems from vendors. Variations included Tofts model vs. Shutter-Speed (SSM), ROI- voxel-based...
Motivation: Investigate water exchange rate constant (kio) in monitoring breast cancer (BC) response to neoadjuvant chemotherapy (NAC). Goal(s): Evaluate changes kio and voxel fraction of filtered during NAC. Approach: BC patients treated with NAC underwent longitudinal high spatiotemporal resolution DCE-MRI at three sites using different 3T vendor systems. Voxel values were obtained the shutter-speed modeling a biologically relevant DCE achievable range. Results: Fractions decreased...
Motivation: Validate Shutter-Speed model (SSM) DCE-MRI as a robust predictor of breast cancer (BC) response to neoadjuvant chemotherapy (NAC) in multi-center and multi-vendor platform setting. Goal(s): Compare tumor size, semi-quantitative, quantitative for early prediction NAC response. Approach: BC patients treated with underwent longitudinal high spatiotemporal resolution at three sites using 3T Siemens, GE, or Philips system. Semi-quantitative signal-enhancement-ratio (SER) Tofts (TM)...
Quantitative dynamic contrast-enhanced (DCE) MRI as a promising method for the prediction of breast cancer response to neoadjuvant chemotherapy (NAC) has been demonstrated mostly in single-center and single-vendor platform studies. This preliminary study reports initial experience implementing quantitative DCE-MRI multi-center (MC) multi-vendor (MP) settings predict NAC response. data, including B
Abstract The power of spatial biology lies in the integration multiple scales information from subcellular to tissue scale. Until recently, analysis protein biomarkers tissues was limited a few markers at time using traditional IHC colorimetric or fluorescent readout. Here, we demonstrate ability NanoString’s CosMx™ Spatial Molecular Imager (SMI) platform quantify more than 70 proteins encompassing key targets immuno-oncology and tumor biology, localize analyze expression single cell level....
Abstract Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers specific genomic alterations. Results cohort solid tumors CCND1 amp or mut treated P are reported. Methods: Eligible had measurable disease, ECOG performance status (PS) 0-2, adequate organ function and no standard treatment (tx) options. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Recommended dosing...
Abstract Background: Emerging data supports PARPi combinations, including with immune checkpoint blockade (ICB), as effective therapies in TNBC. The Adaptive Multi-Drug Treatment of Evolving Cancers (AMTEC) trial (NCT03801369) is evaluating the + ICB combination olaparib (ola) durvalumab (durva) mTNBC patients (pts). Deep profiling paired pre- and on-ola monotherapy TNBC biopsies (Bx) key to identifying: i) predictive biomarkers select pts who will benefit from ICB, ii) resistance mechanisms...
Approximately 20% of breast cancer demonstrates amplification the HER2 gene resulting in overexpression protein on cell surface. Effective targeting with anti-HER2 monoclonal antibodies (trastuzumab, pertuzumab, trastuzumab-emtansine) and tyrosine kinase inhibitors (lapatinib) dramatically improves natural history this aggressive disease. Patients HER2-overexpressing (HER2+) achieve higher rates pathologic complete response (pCR) to cytotoxic chemotherapy HER2-targeted therapy neoadjuvant...
585 Background: We previously reported a median tumor volume loss of 88% (range 30-98%) in 13 patients with early stage BRCA1/2 mutant breast cancer treated on neoadjuvant trial the PARP inhibitor talazoparib. The effects inhibition immune aspects TiME early-stage has not been well described. goal this study was to evaluate pre and post-treatment core biopsies from enrolled patients. Methods: Eleven paired were available for examination. Tumor infiltrating lymphocytes (TILs) quantified by...